세계의 비용종 없는 만성 비부비동염(CRSsNP) 시장 인사이트, 역학, 시장 예측(2032년)

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) - Market Insight, Epidemiology And Market Forecast - 2032

US $ 7,500 ￦ 10,268,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,250 ￦ 15,402,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,000 ￦ 20,536,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 22,500 ￦ 30,804,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주요 하이라이트

• 비용종 없는 만성 비부비동염(CRSsNP) 시장은 예측 기간(2023-2032년) 동안 안정된 성장이 예상됩니다. 비용종 없는 만성 비부비동염(CRSsNP) 시장 규모는 인구 증가와 진단 향상으로 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본) 확대될 것으로 예측됩니다.
• 주요 7개 시장 시장은 주로 표준 치료로 구성되어 2022년 약 39억 달러를 창출했습니다.
• 비용종 없는 만성 비부비동염(CRSsNP) 치료 시장의 총 시장 규모는 LYR-210, XHANCE(OPN-375), LYR-220 등 새로운 효과적인 치료제 출현으로 성장이 예상됩니다.

비용종 없는 만성 비부비동염(CRSsNP) 시장 전망

항생제와 코르티코 스테로이드는 현재 치료 상황의 주요 수익원입니다. 항생제와 코르티코 스테로이드(비강, 구강) 사용은 CRSsNP를 관리하기 위해 의료 종사자에게 증거 기반 조언을 제공하는 임상 진료 지침에 의해 안내됩니다.

비용종 없는 만성 비부비동염(CRSsNP) 시장은 LYR-210, OPN-375/XHANCE, LYR-220과 같은 잠재 약물 승인에 의해 플러스 성장이 예측됩니다.

세계의 비용종 없는 만성 비부비동염(CRSsNP : Chronic Rhinosinusitis without Nasal Polyps) 주요 7개 시장 조사 분석을 수행했으며 시장 규모와 예측, 현재 치료법 및 신약 정보 등을 제공합니다.

목차

제1장 주요 고찰

제2장 보고서 소개

제3장 비용종 없는 만성 비부비동염(CRSsNP) 시장 주요 요약 : 국가별

• 비용종 없는 만성 비부비동염(CRSsNP) 시장 점유율 분포 : 국가별(2019년)
• 비용종 없는 만성 비부비동염(CRSsNP) 시장 점유율 분포 : 국가별(2032년)

제4장 비용종 없는 만성 비부비동염(CRSsNP) 시장 주요 요약:치료법별

• 비용종 없는 만성 비부비동염(CRSsNP) 시장 점유율 분포 : 치료법별(2019년)
• 비용종 없는 만성 비부비동염(CRSsNP) 시장 점유율 분포 : 치료법별(2032년)

제5장 비용종 없는 만성 비부비동염(CRSsNP) 조사 방법 역학과 시장

제6장 비버섯이 없는만성 부비강염(CRSsNP) 주요 요약

제7장 주요 사건

제8장 질병 배경과 주요 요약 : CRSsNP

• 소개
• 표현형과 엔드 유형
• 유전학
• 병인
• 병태생리학
• 징후와 증상
• 진단
  • 진단 기준
  • 진단 알고리즘
• 치료 및 관리
  • 치료 알고리즘
  • 치료 가이드라인

제9장 역학과 환자 수

• 주요 조사 결과
• 전제조건 및 근거 : 주요 7개 시장
  • 미국
  • 유럽 4개국(독일, 프랑스, 이탈리아, 스페인), 영국
  • 일본
• 주요 7개 시장 CRS로 진단된 사례 총수
• 주요 7개 시장 비용종 없는 만성 비부비동염(CRSsNP)으로 진단된 증례 총수
• 미국
• 유럽 4개국, 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본

제10장 페이센트 저니

제11장 신약

• 주요 경쟁
• XHANCE(fluticasone propionate)/OPN-375 : Optinose US Inc.
• LYR-210 : lyra Therapeutics
• LYR-220 : lyra Therapeutics
• Brensocatib : Insmedlinc. DUPIXENT(dupilumab) : Sanofi/Regeneron Pharmaceuticals

제12장 CRSsNP : 시장 분석

• 주요 조사 결과
• 주요 시장 예측 전제조건
• 시장 전망
• 컨조인트 분석
• 주요 7시장 코버섯을 수반하지 않는만성 부비강염(CRSsNP) 시장 규모
• 주요 7시장 코버섯을 수반하지 않는만성 부비강염(CRSsNP) 시장 규모 : 치료법별
• 미국 시장 규모
  • 미국 비용종 없는 만성 비부비동염(CRSsNP) 총 시장 규모
  • 미국 비용종 없는 만성 비부비동염(CRSsNP) 시장 규모 : 치료법별
• 유럽 4개국, 영국 시장 규모
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본 시장 규모
  • 일본 비용종 없는 만성 비부비동염(CRSsNP) 시장 규모
  • 일본 비용종 없는 만성 비부비동염(CRSsNP) 시장 규모 : 치료법별

제13장 주요 오피니언 리더 견해

제14장 SWOT 분석

제15장 미충족 요구

제16장 시장 진입과 상환

• 미국
• 유럽 4개국, 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본

제17장 부록

제18장 보고서 조사 방법

제19장 DelveInsight 서비스 내용

제20장 면책 사항

NJH

영문 목차

영문목차

Key Highlights:

• The Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM is expected to increase, driven by an increase in the population and better diagnosis.
• DelveInsight's analyst projects that approximately 81% of individuals diagnosed with CRS belong to the Chronic Rhinosinusitis Without Nasal Polyps category in the US. As per our estimations, in 2022, the US accounted for 8.8 million diagnosed prevalent cases of CRSsNP.
• As per DelveInsight's analysis, EU4 and the UK comprised around 42% of the diagnosed prevalent cases of Chronic Rhinosinusitis Without Nasal Polyps in 2022 among the 7MM.
• Japan accounted for more than 1.1 million diagnosed prevalent cases of Chronic Rhinosinusitis Without Nasal Polyps in 2022.
• In the 7MM, the market mainly consisted of standard of care, which generated nearly USD 3.9 billion in 2022.
• The total market size of the Chronic Rhinosinusitis Without Nasal Polyps treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, LYR-210, XHANCE (OPN-375), and LYR-220, among others.

DelveInsight's "Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The chronic rhinosinusitis without nasal polyps market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM chronic rhinosinusitis without nasal polyps market size from 2019 to 2032. The report also covers current chronic rhinosinusitis without nasal polyps treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Disease Understanding and Treatment Algorithm

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Overview

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a prevalent and chronic medical condition characterized by inflammation and swelling of the nasal passages and paranasal sinuses, but notably, it does not involve the presence of nasal polyps.

Individuals with chronic rhinosinusitis without nasal polyps often experience symptoms such as nasal congestion, difficulty breathing through the nose, facial pain or pressure, reduced sense of smell (hyposmia), and a persistent discharge from the nose. These symptoms typically last more than 12 weeks, making it a chronic condition requiring proper management.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Diagnosis

Diagnosing chronic rhinosinusitis without nasal polyps involves a thorough examination of the nasal passages and sinuses by medical professionals, who may also consider the patient's medical history and the duration of symptoms to differentiate it from other similar conditions. The diagnosis is typically based on specific diagnostic criteria established by medical guidelines. These criteria include two or more of the following major symptoms: nasal blockage/congestion, nasal discharge, facial pain/pressure, and reduced sense of smell. The symptoms of CRSsNP must be present for at least 12 consecutive weeks to meet the diagnosis. In some cases, the doctor may order imaging studies, such as a CT scan of the sinuses.

Further details related to country-based variations are provided in the report.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Treatment

Treatment for chronic rhinosinusitis without nasal polyps alleviates inflammation and effectively manages symptoms. Medical management may include the use of nasal corticosteroids to reduce inflammation and antibiotics if there is evidence of a bacterial infection. Nasal irrigations or rinses with saline solutions may also be recommended to help improve nasal health and provide relief. If medical treatment fails to provide sufficient symptom relief or disease control, surgical interventions such as endoscopic sinus surgery (ESS) may be considered.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Epidemiology

As the market is derived using the patient-based model, the chronic rhinosinusitis without nasal polyps epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), and Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of chronic rhinosinusitis without nasal polyps in the 7MM was approximately 17 million cases in 2022 and are projected to increase during the forecast period.

• In 2022, among the 7MM, the US recorded the highest number of prevalent cases of Chronic Rhinosinusitis (CRS), with approximately 31 million cases. Across all the 7MM countries, the total number of prevalent CRS cases was approximately 71 million, and these cases are projected to increase by 2032.
• In 2022, there were an estimated 9 million diagnosed cases of CRS out of a total of 31 million prevalent cases in EU4 and the UK.
• DelveInsight's analysis indicates that approximately 81% of the total diagnosed cases of CRS in the 7MM were diagnosed as chronic rhinosinusitis without nasal polyps accounting for about 17 million cases in the 7MM, among which the US accounted for 51% of the cases.
• The assessment indicates that the number of chronic rhinosinusitis without nasal polyps cases in Japan is projected to decrease at a significant CAGR during the forecast period (2023-2032) due to a declining population.
• The United States has the highest number of diagnosed cases of chronic rhinosinusitis without nasal polyps in females compared to males. In 2022, of all chronic rhinosinusitis without nasal polyps cases, approximately 63% were females, while around 37% of males were diagnosed with the condition.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Drug Chapters

The drug chapter segment of the chronic rhinosinusitis without nasal polyps report encloses a detailed analysis of chronic rhinosinusitis without nasal polyps marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands chronic rhinosinusitis without nasal polyps clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

XHANCE (fluticasone propionate)/OPN-375: Optinose US Inc.

Optinose US Inc.'s first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 µg, is therapeutic, utilizing a proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and if approved, chronic rhinosinusitis without nasal polyps. In September 2017, the US FDA approved XHANCE for treating nasal polyps in patients aged 18 or older, and it was made widely available through commercial channels in April 2018. This product candidate is currently in Phase III of its clinical development for CRSsNP.

LYR-210: Lyra Therapeutics

LYR-210 is an anti-inflammatory implantable drug matrix designed to consistently and locally elute mometasone furoate, or MF, to the inflamed mucosal tissue for up to 6 months in surgically naive CRS patients with and without nasal polyps who have failed previous medical management. LYR-210 is undergoing a Phase III program, the ENLIGHTEN, comprising two pivotal trials. These trials are currently in progress and are crucial in determining the drug's efficacy and safety. Both trials will enroll surgically naive CRS patients in the US and Europe to support the company's FDA submission.

Note: Detailed emerging therapies assessment will be provided in the final report of CRSsNP.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Outlook

Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient's quality of life.

Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP.

The market for chronic rhinosinusitis without nasal polyps is expected to experience positive growth with the approval of potential drugs like LYR-210, OPN-375/ XHANCE, and LYR-220.

• The Chronic Rhinosinusitis with Nasal Polyps (CRSsNP) market's total size in the 7MM reached approximately USD 3.9 billion in 2022. Projections indicate a substantial CAGR from 2022 to 2032.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at 64%.
• In 2022, EU4 and the UK captured nearly 31% and Japan around 5% of the total market share in the 7MM.
• Among the forecasted emerging therapies, LYR-210 is expected to capture the highest market in the 7MM by 2032.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, LYR-210 in the US is expected to have medium-fast drug uptake with a probability-adjusted peak share of around 12%, and years to the peak is expected to be 6 years from the year of launch.

Further detailed analysis of emerging therapies drug uptake in the report…

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for chronic rhinosinusitis without nasal polyps emerging therapies.

KOL Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on chronic rhinosinusitis without nasal polyps evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Surgery, Ralph H. Johnson VA Medical Center; Department of Otorhinolaryngology, Ulm University Medical Center, Frauensteige; Department of Allergy and Medical Rhinology, University College London, London; Department of Pediatrics, Nippon Medical School, Tokyo, and others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or chronic rhinosinusitis without nasal polyps market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Insights

• Patient Population
• Therapeutic Approaches
• Chronic Rhinosinusitis Without Nasal Polyps Pipeline Analysis
• Chronic Rhinosinusitis Without Nasal Polyps Market Size and Trends
• Existing and Future Market Opportunity

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What will be the impact of the XHANCE patent expiry in the market?
• How will XHANCE compete with the existing therapies for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) during the study period?
• Which drug is going to be the largest contributor in 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What is the historical and forecasted Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which type of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) is more prevalent and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)? What are the current guidelines for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in the US and Europe?
• How many companies are developing therapies for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• How many emerging therapies are in the mid-stage and late stage of development for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Country-wise Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview at a Glance

• 3.1. Country-wise Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps in 2019
• 3.2. Country-wise Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps in 2032

4. Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview by Therapies

• 4.1. Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in 2019
• 4.2. Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in 2032

5. Methodology of Chronic Rhinosinusitis Without Nasal Polyps Epidemiology and Market

6. Executive Summary of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

7. Key Events

8. Disease Background and Overview: CRSsNP

• 8.1. Introduction
• 8.2. Phenotypes and Endotypes
• 8.3. Genetics
• 8.4. Pathogenesis
• 8.5. Pathophysiology
• 8.6. Signs and Symptoms
• 8.7. Diagnosis
  • 8.7.1. Diagnosis Criteria
    • 8.7.1.1. EUFOREA Rhinology Research Forum 2016
    • 8.7.1.2. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis (ECRS)
  • 8.7.2. Diagnostic Algorithm
• 8.8. Treatment and Management
  • 8.8.1. Treatment Algorithm
  • 8.8.2. Treatment Guidelines
    • 8.8.2.1. EPOS Primary Care Guidelines
    • 8.8.2.2. International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. The United States
  • 9.2.2. EU4 (Germany, France, Italy, Spain) and the United Kingdom
  • 9.2.3. Japan
• 9.3. Total Diagnosed Prevalent Cases of CRS in the 7MM
• 9.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 9.5. The United States
  • 9.5.1. Total Prevalent Cases of CRS in the US
  • 9.5.2. Total Diagnosed Prevalent Cases of CRS in the US
  • 9.5.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US
  • 9.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US
• 9.6. EU4 and the UK
  • 9.6.1. Germany
    • 9.6.1.1. Total Prevalent Cases of CRS in Germany
    • 9.6.1.2. Total Diagnosed Prevalent Cases of CRS in Germany
    • 9.6.1.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany
    • 9.6.1.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany
  • 9.6.2. France
    • 9.6.2.1. Total Prevalent Cases of CRS in France
    • 9.6.2.2. Total Diagnosed Prevalent Cases of CRS in France
    • 9.6.2.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France
    • 9.6.2.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France
  • 9.6.3. Italy
    • 9.6.3.1. Total Prevalent Cases of CRS in Italy
    • 9.6.3.2. Total Diagnosed Prevalent Cases of CRS in Italy
    • 9.6.3.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy
    • 9.6.3.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy
  • 9.6.4. Spain
    • 9.6.4.1. Total Prevalent Cases of CRS in Spain
    • 9.6.4.2. Total Diagnosed Prevalent Cases of CRS in Spain
    • 9.6.4.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain
    • 9.6.4.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain
  • 9.6.5. The UK
    • 9.6.5.1. Total Prevalent Cases of CRS in the UK
    • 9.6.5.2. Total Diagnosed Prevalent Cases of CRS in the UK
    • 9.6.5.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK
    • 9.6.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK
• 9.7. Japan
  • 9.7.1. Total Prevalent Cases of CRS in Japan
  • 9.7.2. Total Diagnosed Prevalent Cases of CRS in Japan
  • 9.7.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan
  • 9.7.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan

10. Patient Journey

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. XHANCE (fluticasone propionate)/OPN-375: Optinose US Inc.
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activity
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. LYR-210: Lyra Therapeutics
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activity
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. LYR-220: Lyra Therapeutics
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activity
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Product Profile
  • 11.4.7. Analysts' Views
• 11.5. Brensocatib: Insmed, Inc. DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activity
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Product Profile
  • 11.5.6. Analysts' Views
• . Detailed list to be provided in the report.

12. CRSsNP: Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
• 12.3. Market Outlook
• 12.4. Conjoint Analysis
• 12.5. Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 12.6. Market Size by Therapies of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 12.7. The United States Market Size
  • 12.7.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the United States
  • 12.7.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the United States
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Germany
    • 12.8.1.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Germany
    • 12.8.1.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Germany
  • 12.8.2. France
    • 12.8.2.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in France
    • 12.8.2.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in France
  • 12.8.3. Italy
    • 12.8.3.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Italy
    • 12.8.3.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Italy
  • 12.8.4. Spain
    • 12.8.4.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Spain
    • 12.8.4.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Spain
  • 12.8.5. The UK
    • 12.8.5.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the UK
    • 12.8.5.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the UK
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Japan
  • 12.9.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Japan

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

관련자료